ReviewHematology, transfusion and cell therapy2026
Extracorporeal photopheresis: A comprehensive review from a transfusion medicine perspective.
Review in Hematology, transfusion and cell therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracorporeal photopheresis is a unique immunomodulatory therapy that involves the ex vivo treatment of leukocytes with 8-methoxypsoralen and ultraviolet A light, followed by reinfusion into the patient. Initially developed for cutaneous T-cell lymphoma, extracorporeal photopheresis has gained recognition for its efficacy in treating various immune-mediated conditions such as graft-versus-host disease, systemic sclerosis, solid organ transplant rejection, and inflammatory bowel diseases. This review outlines the historical evolution, pharmacology of psoralens, mechanisms of action, clinical applications, equipment types, quality control methods and practical aspects for initiating extracorporeal photopheresis. The therapy's core mechanism, inducing apoptosis and modulating dendritic cell function, promotes immune tolerance and regulatory T-cell expansion. Different inline and offline systems are employed, each with distinct operational and safety considerations. Current evidence supports extracorporeal photopheresis in steroid-refractory graft-versus-host disease and cutaneous T-cell lymphoma, although its role in visceral and long-term disease remains underexplored. Quality control methods such as proliferation assays, flow cytometry, and surrogate markers are discussed in detail. Despite its promise, further randomized trials are necessary to clarify standardized protocols and long-term outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.